BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

(2017) Pengfei Wang et al.   Scientific Reports

A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association

(2017) Huachao Huang et al.   Frontiers in Microbiology

Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4+ T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb

(2016) Md Saha Jamaluddin et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease

(2016) Dean Gilham et al.   ATHEROSCLEROSIS

Reversal of Latency as Part of a Cure for HIV-1

(2016) Thomas Aagaard Rasmussen et al.   TRENDS IN MICROBIOLOGY

HIV-1 Eradication: Early Trials (and Tribulations)

(2016) Adam M. Spivak et al.   TRENDS IN MOLECULAR MEDICINE

The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb

(2016) Panpan Lu et al.   Scientific Reports

Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents

(2016) Héloïse M. Delagrèverie et al.   Open Forum Infectious Diseases

Progress and challenges in the use of latent HIV-1 reactivating agents

(2015) Hong-tao Shang et al.   ACTA PHARMACOLOGICA SINICA

Short Communication: SAHA (Vorinostat) Induces CDK9 Thr-186 (T-Loop) Phosphorylation in Resting CD4+ T Cells: Implications for Reactivation of Latent HIV

(2015) Rajesh Ramakrishnan et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

An evaluation of RVX-208 for the treatment of atherosclerosis

(2015) Dragana Nikolic et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations

(2015) Gregory M. Laird et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors

(2015) R Gopalakrishnan et al.   ONCOGENE

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

(2015) Gilles Darcis et al.   PLoS Pathogens

Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

(2015) Guochun Jiang et al.   PLoS Pathogens

A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice

(2014) Ravi Jahagirdar et al.   ATHEROSCLEROSIS

New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo

(2014) C Korin Bullen et al.   NATURE MEDICINE

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist

(2014) Kevin G. McLure et al.   PLoS One

Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

(2014) Datsen George Wei et al.   PLoS Pathogens

As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB

(2013) Pengfei Wang et al.   ANTIVIRAL RESEARCH

PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains

(2013) S. Picaud et al.   CANCER RESEARCH

BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism

(2013) Daniela Boehm et al.   CELL CYCLE

BET bromodomain inhibitors: a patent review

(2013) Jean-Marc Garnier et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

A Novel PCR Assay for Quantification of HIV-1 RNA

(2013) L. Shan et al.   JOURNAL OF VIROLOGY

Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells

(2013) Xiying Qu et al.   NUCLEIC ACIDS RESEARCH

Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation

(2013) Donglin Ding et al.   VIROLOGY

RVX 208

(2013)   Drugs in research & development

HIV-1 eradication strategies

(2013) Janet D. Siliciano et al.   Current Opinion in HIV and AIDS

Phosphorylation of CDK9 at Ser175 Enhances HIV Transcription and Is a Marker of Activated P-TEFb in CD4+ T Lymphocytes

(2013) Uri R. Mbonye et al.   PLoS Pathogens

ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies

(2012) Stephen J. Nicholls et al.   CARDIOVASCULAR DRUGS AND THERAPY

Targeting HIV latency: pharmacologic strategies toward eradication

(2012) Sifei Xing et al.   DRUG DISCOVERY TODAY

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

(2012) Camellia Banerjee et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Identification of a Chemical Probe for Bromo and Extra C-Terminal Bromodomain Inhibition through Optimization of a Fragment-Derived Hit

(2012) Paul V. Fish et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cyclin T1 and CDK9 T-Loop Phosphorylation Are Downregulated during Establishment of HIV-1 Latency in Primary Resting Memory CD4+ T Cells

(2012) S. Budhiraja et al.   JOURNAL OF VIROLOGY

Shock and kill

(2012) Steven G. Deeks   NATURE

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation

(2012) Zichong Li et al.   NUCLEIC ACIDS RESEARCH

Novel HDL-based therapeutic agents

(2012) Tisha R. Joy   PHARMACOLOGY & THERAPEUTICS

Selective Histonedeacetylase Inhibitor M344 Intervenes in HIV-1 Latency through Increasing Histone Acetylation and Activation of NF-kappaB

(2012) Hao Ying et al.   PLoS One

Identification of novel CDK9 and Cyclin T1-associated protein complexes (CCAPs) whose siRNA depletion enhances HIV-1 Tat function

(2012) Rajesh Ramakrishnan et al.   Retrovirology

Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease

(2011) Stephen J. Nicholls et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

RVX-208

(2010) Dana Bailey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Controlling Cellular P-TEFb Activity by the HIV-1 Transcriptional Transactivator Tat

(2010) Lisa Muniz et al.   PLoS Pathogens

Characterization of Cdk9 T-loop phosphorylation in resting and activated CD4+ T lymphocytes

(2009) Rajesh Ramakrishnan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Transcriptional Restriction of Human Immunodeficiency Virus Type 1 Gene Expression in Undifferentiated Primary Monocytes

(2009) C. Dong et al.   JOURNAL OF VIROLOGY

The Challenge of Finding a Cure for HIV Infection

(2009) D. D. Richman et al.   SCIENCE